1 / 10

Sickle Cell Disease Market Insight, Epidemiology and Market Forecast - 2028

Sickle Cell disease, which is also known as sickle cell anaemia. It includes a group of disorders that affect the red blood cells.<br> <br>Sickle Cell disease is an inherited blood disorder that is distinguished by defective haemoglobin. The changes in which red blood cells behave differently are dehydration, low oxygen levels and elevated temperature, which may cause the red blood cells to block the small blood vessels, restricting blood flow.<br>

sthakur
Télécharger la présentation

Sickle Cell Disease Market Insight, Epidemiology and Market Forecast - 2028

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SICKLE CELL DISEASE Market Insights, Epidemiology and Market Forecast-2028

  2. Sickle Cell Disease Sickle Cell Disease, also known as sickle cell anemia, includes group of disorders affecting the red blood cells in the body. It is an inherited blood disorder characterized by defective hemoglobin. In this disease, there aren't enough healthy red blood cells to carry adequate oxygen throughout the body. Sickle cell disease is irreversible that affects males and females equally, and is responsible for increased morbidity and mortality in affected persons. • DelveInsight © 2019 | All rights reserved

  3. Sickle Cell Disease Epidemiology Among the EU5 countries, France has the highest prevalent population with 15,000 cases followed by the United Kingdom, which has a prevalent population of 13,000 in 2017. There is no Sickle Cell Disease prevalence in Japan since the disease doesn’t occur in the Japanese population There were approximately 133,385 Sickle Cell Disease prevalent cases in 2017 in the 6MM. The United States accounts for the highest Sickle Cell Disease prevalent population followed by the EU5 countries. • DelveInsight © 2019 | All rights reserved

  4. Sickle Cell Disease Market Most of Sickle Cell Disease treatments are dominated by off label and off patent medications (HU; Iron Chelators, Analgesics, Antibiotics, vaccines), to address the complications or for specific Sickle Cell Disease symptoms. Hydroxyurea was the first ever drug approved for Sickle Cell Disease treatment in 1998. The most distressing issue with Hydroxyurea was the lack of FDA approval for infants with Sickle Cell Disease in the United States. Sickle Cell Disease market size was majorly dependent on the use of Hydroxyurea till 2017, when Endari was launched. The approval of the Emmaus’s Endari for treating Sickle Cell Disease complications in the United States in 2017 had marked a significant advancement in Sickle Cell Disease treatment. Companies are working on novel mechanisms of action (Pan-Selection Inhibitor) will further fuel the Sickle Cell Disease market growth. • DelveInsight © 2019 | All rights reserved

  5. Sickle Cell Disease Emerging Drugs and Companies 01 02 03 04 Company- GBT Therapeutics Drug- Voxelotor/ GBT-440 Company- Pfizer Drug- Rivipansel Company- Novartis Drug- Crizanlizumab Company- Imara Therapeutics Drug- IMR-687 • DelveInsight © 2019 | All rights reserved

  6. Complete Information For complete information on Sickle Cell Disease Market Insight, Epidemiology and Market Forecast - 2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  7. About DelveInsight ABOUT MISSION VISION DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved

  8. Service Offerings By DelveInsight OPPORTUNITY ASSESSMENT FORECASTING PIPELINE REPORT STORE COMPETITIVE ANALYSIS CONSULTING MARKET INTELLIGENCE PHARMDELVE • DelveInsight © 2019 | All rights reserved

  9. Contact Us blog/delveInsight/ info@delveinsight.com +91-11-4568 9769 twitter/delveInsight LinkedIn/delveInsight www.delveinsight.com • DelveInsight © 2019 | All rights reserved

  10. THANK YOU

More Related